Synchrony is an early stage pre-seed start-up that is aimed at development of a novel anticancer treatment paradigm. Our first target, colorectal cancer (CRC) is the 2nd most common cause of cancer death in the UK. 41,700 new cases in UK annually and an average of 43% mortality demonstrate a massive unmet patient need. We aim to establish a novel framework technology that can be expanded into other cancer types and allow Big Pharma to repurpose their compounds.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Oxford, Oxfordshire, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Seal Biosciences.
- HQ
- Oxford, Oxfordshire
Synchrony Questions
Synchrony's LinkedIn profile is https://uk.linkedin.com/company/synchrony-biotech
Synchrony has
2 employees.
View email and phone details for 2
employees at Synchrony.
Synchrony's industry is
Biotechnology Research
Synchrony's top competitors are
Stimuli,
Epigenetic Data Sciences,
Metimedi Co., Ltd.,
Seal Biosciences,
Mitophilix,
St Innovative Diagnostics Ltd.,
Theravax,
St-Diagnostic,
Chess Therapeutics, Llc,
Rhemastem Srls.
Synchrony's categories are Biotechnology Research
Synchrony's founding year is 2019
